Explore
Trendline
BrainStorm Cell Therapeutics Announces Financial Results and Updates on ALS Treatment Development
BrainStorm Cell Therapeutics Announces Financial Results and Updates on ALS Treatment Development
Read More
Trendline
Brainstorm Cell Therapeutics Reports Narrowed Losses in Q1 2026
Brainstorm Cell Therapeutics Reports Narrowed Losses in Q1 2026
Read More
Trendline
Nanoviricides Reports Third Quarter Loss Amid Clinical Advancements
Nanoviricides Reports Third Quarter Loss Amid Clinical Advancements
Read More
Trendline
Biogen Advances Alzheimer's Drug Diranersen Despite Phase 2 Trial Setback
Biogen Advances Alzheimer's Drug Diranersen Despite Phase 2 Trial Setback
Read More
Trendline
NanoViricides Reports $1.99M Net Loss in Q3 FY2026 Amid Clinical Advancements
NanoViricides Reports $1.99M Net Loss in Q3 FY2026 Amid Clinical Advancements
Read More
Trendline
Spruce Biosciences Reports Q1 2026 Financial Results and Corporate Updates
Spruce Biosciences Reports Q1 2026 Financial Results and Corporate Updates
Read More
Trendline
INOVIO Reports First Quarter 2026 Financial Results Amid Regulatory Review of INO-3107
INOVIO Reports First Quarter 2026 Financial Results Amid Regulatory Review of INO-3107
Read More
Trendline
Longeveron Reports Q1 Financial Results and Strategic Updates
Longeveron Reports Q1 Financial Results and Strategic Updates
Read More
Trendline
Atara Biotherapeutics Reports Significant Revenue Decline and Operational Updates for Q1 2026
Atara Biotherapeutics Reports Significant Revenue Decline and Operational Updates for Q1 2026
Read More
Trendline
Palatin Technologies Reports Q3 2026 Financial Results and Business Update
Palatin Technologies Reports Q3 2026 Financial Results and Business Update
Read More
Trendline
Fosun Pharma and AriBio Sign Agreement for Alzheimer's Drug Development
Fosun Pharma and AriBio Sign Agreement for Alzheimer's Drug Development
Read More
Trendline
Longeveron Reports Q1 2026 Financial Results and Strategic Developments in Stem Cell Therapy
Longeveron Reports Q1 2026 Financial Results and Strategic Developments in Stem Cell Therapy
Read More
